IBEX LTD (IBEX) Fundamental Analysis & Valuation

NASDAQ:IBEX • BMG4690M1010

Current stock price

28.74 USD
-0.98 (-3.3%)
At close:
28.74 USD
0 (0%)
After Hours:

This IBEX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. IBEX Profitability Analysis

1.1 Basic Checks

  • IBEX had positive earnings in the past year.
  • IBEX had a positive operating cash flow in the past year.
  • IBEX had positive earnings in each of the past 5 years.
  • In the past 5 years IBEX always reported a positive cash flow from operatings.
IBEX Yearly Net Income VS EBIT VS OCF VS FCFIBEX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M 40M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 14.98%, IBEX belongs to the top of the industry, outperforming 94.32% of the companies in the same industry.
  • IBEX has a Return On Equity of 28.69%. This is amongst the best in the industry. IBEX outperforms 90.91% of its industry peers.
  • IBEX has a better Return On Invested Capital (21.96%) than 96.59% of its industry peers.
Industry RankSector Rank
ROA 14.98%
ROE 28.69%
ROIC 21.96%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IBEX Yearly ROA, ROE, ROICIBEX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 100

1.3 Margins

  • IBEX has a better Profit Margin (7.35%) than 67.05% of its industry peers.
  • IBEX's Profit Margin has improved in the last couple of years.
  • The Operating Margin of IBEX (9.38%) is better than 69.32% of its industry peers.
  • IBEX's Operating Margin has improved in the last couple of years.
  • Looking at the Gross Margin, with a value of 30.36%, IBEX is in line with its industry, outperforming 44.32% of the companies in the same industry.
  • In the last couple of years the Gross Margin of IBEX has remained more or less at the same level.
Industry RankSector Rank
OM 9.38%
PM (TTM) 7.35%
GM 30.36%
OM growth 3Y27.75%
OM growth 5Y12.6%
PM growth 3Y14.82%
PM growth 5Y27.95%
GM growth 3Y0.55%
GM growth 5YN/A
IBEX Yearly Profit, Operating, Gross MarginsIBEX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. IBEX Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so IBEX is creating value.
  • There is no outstanding debt for IBEX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
IBEX Yearly Shares OutstandingIBEX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
IBEX Yearly Total Debt VS Total AssetsIBEX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • IBEX has an Altman-Z score of 4.84. This indicates that IBEX is financially healthy and has little risk of bankruptcy at the moment.
  • With an excellent Altman-Z score value of 4.84, IBEX belongs to the best of the industry, outperforming 81.82% of the companies in the same industry.
  • The Debt to FCF ratio of IBEX is 0.05, which is an excellent value as it means it would take IBEX, only 0.05 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 0.05, IBEX belongs to the top of the industry, outperforming 90.91% of the companies in the same industry.
  • IBEX has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
  • IBEX's Debt to Equity ratio of 0.00 is amongst the best of the industry. IBEX outperforms 81.82% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.05
Altman-Z 4.84
ROIC/WACC2.03
WACC10.81%
IBEX Yearly LT Debt VS Equity VS FCFIBEX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M 150M

2.3 Liquidity

  • A Current Ratio of 1.83 indicates that IBEX should not have too much problems paying its short term obligations.
  • IBEX has a Current ratio of 1.83. This is comparable to the rest of the industry: IBEX outperforms 54.55% of its industry peers.
  • IBEX has a Quick Ratio of 1.83. This is a normal value and indicates that IBEX is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 1.83, IBEX is in line with its industry, outperforming 54.55% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.83
Quick Ratio 1.83
IBEX Yearly Current Assets VS Current LiabilitesIBEX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. IBEX Growth Analysis

3.1 Past

  • IBEX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 44.77%, which is quite impressive.
  • The Earnings Per Share has been growing by 41.04% on average over the past years. This is a very strong growth
  • The Revenue has grown by 15.63% in the past year. This is quite good.
  • Measured over the past years, IBEX shows a small growth in Revenue. The Revenue has been growing by 6.62% on average per year.
EPS 1Y (TTM)44.77%
EPS 3Y28.16%
EPS 5Y41.04%
EPS Q2Q%47.46%
Revenue 1Y (TTM)15.63%
Revenue growth 3Y4.24%
Revenue growth 5Y6.62%
Sales Q2Q%16.73%

3.2 Future

  • IBEX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.47% yearly.
  • IBEX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.15% yearly.
EPS Next Y24.4%
EPS Next 2Y15.47%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year14.81%
Revenue Next 2Y10.15%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
IBEX Yearly Revenue VS EstimatesIBEX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M
IBEX Yearly EPS VS EstimatesIBEX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

8

4. IBEX Valuation Analysis

4.1 Price/Earnings Ratio

  • IBEX is valuated reasonably with a Price/Earnings ratio of 8.31.
  • Based on the Price/Earnings ratio, IBEX is valued cheaper than 88.64% of the companies in the same industry.
  • IBEX's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.95.
  • With a Price/Forward Earnings ratio of 7.70, the valuation of IBEX can be described as very cheap.
  • Based on the Price/Forward Earnings ratio, IBEX is valued cheaper than 88.64% of the companies in the same industry.
  • IBEX's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 38.68.
Industry RankSector Rank
PE 8.31
Fwd PE 7.7
IBEX Price Earnings VS Forward Price EarningsIBEX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • 93.18% of the companies in the same industry are more expensive than IBEX, based on the Enterprise Value to EBITDA ratio.
  • 73.86% of the companies in the same industry are more expensive than IBEX, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 13.16
EV/EBITDA 5
IBEX Per share dataIBEX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40

4.3 Compensation for Growth

  • IBEX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of IBEX may justify a higher PE ratio.
  • A more expensive valuation may be justified as IBEX's earnings are expected to grow with 15.47% in the coming years.
PEG (NY)0.34
PEG (5Y)0.2
EPS Next 2Y15.47%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. IBEX Dividend Analysis

5.1 Amount

  • IBEX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IBEX Fundamentals: All Metrics, Ratios and Statistics

IBEX LTD

NASDAQ:IBEX (4/20/2026, 8:07:11 PM)

After market: 28.74 0 (0%)

28.74

-0.98 (-3.3%)

Chartmill FA Rating
GICS IndustryGroupSoftware & Services
GICS IndustryIT Services
Earnings (Last)02-05
Earnings (Next)05-06
Inst Owners96.54%
Inst Owner Change-0.73%
Ins Owners6.46%
Ins Owner Change16.26%
Market Cap385.40M
Revenue(TTM)603.27M
Net Income(TTM)44.32M
Analysts45.71
Price Target38.25 (33.09%)
Short Float %1.54%
Short Ratio1.28
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.35%
Min EPS beat(2)8.65%
Max EPS beat(2)20.05%
EPS beat(4)4
Avg EPS beat(4)15.36%
Min EPS beat(4)8.65%
Max EPS beat(4)21.85%
EPS beat(8)8
Avg EPS beat(8)15.45%
EPS beat(12)10
Avg EPS beat(12)11.12%
EPS beat(16)13
Avg EPS beat(16)15.27%
Revenue beat(2)2
Avg Revenue beat(2)3.02%
Min Revenue beat(2)2.5%
Max Revenue beat(2)3.54%
Revenue beat(4)4
Avg Revenue beat(4)4.92%
Min Revenue beat(4)2.5%
Max Revenue beat(4)8.52%
Revenue beat(8)6
Avg Revenue beat(8)2.69%
Revenue beat(12)6
Avg Revenue beat(12)0.39%
Revenue beat(16)7
Avg Revenue beat(16)-0.19%
PT rev (1m)-8.54%
PT rev (3m)-8.54%
EPS NQ rev (1m)-3.93%
EPS NQ rev (3m)-6.04%
EPS NY rev (1m)0.89%
EPS NY rev (3m)1.19%
Revenue NQ rev (1m)0.45%
Revenue NQ rev (3m)1.36%
Revenue NY rev (1m)0.87%
Revenue NY rev (3m)1.77%
Valuation
Industry RankSector Rank
PE 8.31
Fwd PE 7.7
P/S 0.64
P/FCF 13.16
P/OCF 6.52
P/B 2.49
P/tB 2.7
EV/EBITDA 5
EPS(TTM)3.46
EY12.04%
EPS(NY)3.73
Fwd EY12.99%
FCF(TTM)2.18
FCFY7.6%
OCF(TTM)4.41
OCFY15.33%
SpS44.99
BVpS11.52
TBVpS10.64
PEG (NY)0.34
PEG (5Y)0.2
Graham Number29.9502 (4.21%)
Profitability
Industry RankSector Rank
ROA 14.98%
ROE 28.69%
ROCE 27.05%
ROIC 21.96%
ROICexc 23.71%
ROICexgc 25.25%
OM 9.38%
PM (TTM) 7.35%
GM 30.36%
FCFM 4.85%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y27.75%
OM growth 5Y12.6%
PM growth 3Y14.82%
PM growth 5Y27.95%
GM growth 3Y0.55%
GM growth 5YN/A
F-Score8
Asset Turnover2.04
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.05
Debt/EBITDA 0.01
Cap/Depr 168.3%
Cap/Sales 4.94%
Interest Coverage 42.98
Cash Conversion 79.5%
Profit Quality 66.06%
Current Ratio 1.83
Quick Ratio 1.83
Altman-Z 4.84
F-Score8
WACC10.81%
ROIC/WACC2.03
Cap/Depr(3y)83.97%
Cap/Depr(5y)108.52%
Cap/Sales(3y)2.89%
Cap/Sales(5y)3.72%
Profit Quality(3y)75.63%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.77%
EPS 3Y28.16%
EPS 5Y41.04%
EPS Q2Q%47.46%
EPS Next Y24.4%
EPS Next 2Y15.47%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)15.63%
Revenue growth 3Y4.24%
Revenue growth 5Y6.62%
Sales Q2Q%16.73%
Revenue Next Year14.81%
Revenue Next 2Y10.15%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y17.68%
EBIT growth 3Y33.16%
EBIT growth 5Y20.06%
EBIT Next Year70.04%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y50.53%
FCF growth 3Y24.66%
FCF growth 5Y-10.09%
OCF growth 1Y85.57%
OCF growth 3Y4.51%
OCF growth 5Y-2.46%

IBEX LTD / IBEX Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for IBEX LTD?

ChartMill assigns a fundamental rating of 7 / 10 to IBEX.


What is the valuation status for IBEX stock?

ChartMill assigns a valuation rating of 8 / 10 to IBEX LTD (IBEX). This can be considered as Undervalued.


How profitable is IBEX LTD (IBEX) stock?

IBEX LTD (IBEX) has a profitability rating of 7 / 10.


Can you provide the financial health for IBEX stock?

The financial health rating of IBEX LTD (IBEX) is 7 / 10.


Is the dividend of IBEX LTD sustainable?

The dividend rating of IBEX LTD (IBEX) is 0 / 10 and the dividend payout ratio is 0%.